The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency

David W. Rudy, Todd W.B. Gehr, Gary R. Matzke, William G. Kramer, Domenic A. Sica, D. Craig Brater

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

The pharmacodynamics of intravenous and oral torsemide were determined in two randomized crossover clinical trials in patients with chronic renal insufficiency. There was no significant difference in the rate or magnitude of the diuretic response between oral and intravenous administration. As has been shown with other loop diuretics, patients with chronic renal insufficiency have a reduced diuretic response compared with healthy subjects. This diuretic resistance is primarily related to a diminished delivery of drug to the urinary site of action. The response of torsemide at the tubular level is not different from that seen in subjects with normal renal function. Metabolites of torsemide do not appear to contribute to the diuretic response. A dose of 50 to 100 mg dependent on renal function is required to obtain a maximal response. A ceiling dose of approximately 100 mg in patients with chronic renal insufficiency is therefore recommended. Clinical Pharmacology and Therapeutics (1994) 56, 39–47; doi:

Original languageEnglish
Pages (from-to)39-47
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume56
Issue number1
DOIs
StatePublished - Jul 1994

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency'. Together they form a unique fingerprint.

Cite this